Objective To observe the therapeutic effect of kidney-supplementing blood-quickening therapy on Primary osteoporosis（OP）.Methods Totally 240 cases of OP were randomized into the test group of 150 cases and control group of 90 cases.There were 50 patients with kidney-yang deficiency blood stasis pattern

50 patients with kidney-yin deficiency blood stasis pattern and 50 patients with spleen-kidney deficiency blood stasis pattern in the test group

and they were given Gusong Qianggu Formula（骨松强骨方）

Gusong Jiangu Formula（骨松健骨方）and Gusong Yigu Formula（骨松益骨方）respectively.There were 30 patients with kidney-yang deficiency blood stasis pattern

30 patients with kidney-yin deficiency blood stasis pattern and 30 patients with spleen-kidney deficiency blood stasis pattern in the control group

and they were given Xianling Gubao Capsules.Both groups were treated for 12 weeks and followed up to the 48th week.The bone mineral density（BMD）and the levels of bone-specific alkaline phosphatase（BALP）and β-CrossLaps of type I collagen containing cross-linked C-telopeptide（β-CTX）were detected in both groups before and after treatment.The incidence of fragility fractures was observed before treatment and on the 48th week after treatment.Results The total efficacy of BMD in the patients with kidney-yang deficiency blood stasis pattern and spleen-kidney deficiency blood stasis pattern in the test group was 83.33% and 89.8% respectively

which was significantly higher than 50.00% and 37.93% in the control group（P < 0.05）.The β-CTX level and incidence of fragility fractures was significantly decreased in the test group after treatment（P < 0.05 or P < 0.01）

especially in the patients with kidney-yang deficiency blood stasis pattern and spleen-kidney deficiency blood stasis pattern（P < 0.05 or P < 0.01）.Conclusion kidney-supplementing blood-quickening therapy can effectively inhibit bone resorption

prevent decreased BMD and reduce the incidence of fragility fractures in primary OP patients.